Effects of early antigen exposure through lactation on later specific antibody responses in mice.
This study characterized totally the effects of early Ag exposure by the suckling route on later specific antibody responses. When mother mice of BALB/c or C57BL/6 strains were injected with deaggregated human gamma-globulin (HGG) immediately after delivery, total amounts of HGG in sera of offspring increased until 2 wk of age. The catabolism of transferred HGG was extremely slow and the half-life was about 3 wk in both strains. Hence, small amounts of Ag in mothers, 0.5 micrograms in C57BL/6 and 50 micrograms in BALB/c, could tolerize their offspring effectively. As these were minimum tolerogenic doses, the strain difference in ease of tolerance induction is apparent already during suckling. The study on timing dependent effects of HGG-specific antiserum on tolerance induction by mothers given 50 micrograms HGG demonstrated that the tolerance is achieved within the 1st wk of lactation in C57BL/6 offspring, but not in BALB/c offspring, and the restoration from the tolerance needs more than 6 wk under circumstances, supposedly, without free Ag. Whereas the tolerance was induced in a dose-dependent manner in each class of antibody, the dissociation of tolerant states between IgM, IgG, and IgE antibody classes was found in C57BL/6 offspring. It is interesting that C57BL/6 offspring were sensitized weakly, but significantly, by mothers given subtolerogenic doses. However, this was not apparent in BALB/c. Thus, the Ag dose and the animal strain are related closely to the consequences of this Ag exposure. The aging of suckling mice within the first 2 wk of life or immunomodulators administered early in life did not seriously affect the consequences. Studies on a cellular basis showed that the tolerance is caused by the selective defect in helper T cell function and the suppressor cell activity is not associated with the mechanisms. This contrasts with other models of oral tolerance.
Komatsu
T
T
Department of Immunology, Hyogo College of Medicine, Japan.
Okao
M
M
Miyamoto
H
H
Chen
T
T
Shinka
S
S
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000818:Animals; D000833:Animals, Suckling / Q000276:immunology*; D000918:Antibody Specificity / Q000187:drug effects; D000941:Antigens / Q000008:administration & dosage*; D005260:Female; D006023:Glycoproteins / Q000097:blood; D006801:Humans; D007106:Immune Sera / Q000008:administration & dosage; D007108:Immune Tolerance / Q000187:drug effects; D007111:Immunity, Cellular / Q000187:drug effects; D007136:Immunoglobulins / Q000096:biosynthesis*; D007700:Kinetics; D007774:Lactation / Q000187:drug effects; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009363:Neoplasm Proteins; D011247:Pregnancy; D051381:Rats; D011919:Rats, Inbred Strains; D005719:gamma-Globulins / Q000276:immunology* / Q000378:metabolism
D000276:Adjuvants, Immunologic; D000941:Antigens; D006023:Glycoproteins; D007106:Immune Sera; D007136:Immunoglobulins; D009363:Neoplasm Proteins; D005719:gamma-Globulins; C038588:serum immunosuppressive factor, human